- Home
- XPON vs CVKD Comparison
XPON vs CVKD Comparison
Compare XPON & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XPON
- CVKD
- Stock Information
- Founded
- XPON 2016
- CVKD 2022
- Country
- XPON United States
- CVKD United States
- Employees
- XPON N/A
- CVKD N/A
- Industry
- XPON Electronic Components
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- XPON Technology
- CVKD Health Care
- Exchange
- XPON Nasdaq
- CVKD Nasdaq
- Market Cap
- XPON 3.2M
- CVKD 29.5M
- IPO Year
- XPON 2022
- CVKD 2023
- Fundamental
- Price
- XPON $0.90
- CVKD $12.71
- Analyst Decision
- XPON
- CVKD Strong Buy
- Analyst Count
- XPON 0
- CVKD 1
- Target Price
- XPON N/A
- CVKD $32.00
- AVG Volume (30 Days)
- XPON 42.7K
- CVKD 35.8K
- Earning Date
- XPON 08-13-2025
- CVKD 08-06-2025
- Dividend Yield
- XPON N/A
- CVKD N/A
- EPS Growth
- XPON N/A
- CVKD N/A
- EPS
- XPON N/A
- CVKD N/A
- Revenue
- XPON $6,702,411.00
- CVKD N/A
- Revenue This Year
- XPON $61.26
- CVKD N/A
- Revenue Next Year
- XPON N/A
- CVKD N/A
- P/E Ratio
- XPON N/A
- CVKD N/A
- Revenue Growth
- XPON 23.07
- CVKD N/A
- 52 Week Low
- XPON $0.60
- CVKD $5.70
- 52 Week High
- XPON $120.00
- CVKD $22.90
- Technical
- Relative Strength Index (RSI)
- XPON 50.32
- CVKD 49.98
- Support Level
- XPON $0.88
- CVKD $11.00
- Resistance Level
- XPON $0.96
- CVKD $13.56
- Average True Range (ATR)
- XPON 0.08
- CVKD 1.15
- MACD
- XPON -0.00
- CVKD 0.25
- Stochastic Oscillator
- XPON 66.61
- CVKD 80.97
About XPON Expion360 Inc.
Expion360 Inc is focused on the design, assembly, manufacturing, and sales of lithium iron phosphate (LiFePO4) batteries and supporting accessories for recreational vehicles (RV's) and marine applications with plans to expand into home energy storage products and industrial applications. Its product offerings include some of the minimal-footprint batteries in the RV & Marine industry.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.